Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis and Speedel's investigative hypertension drug Rasilez has demonstrated efficacy and, importantly, a good safety profile in the treatment of hypertension in patients with diabetes.
Subscribe to our email newsletter
The data, presented by Novartis at the meeting of the European Society of Hypertension in Madrid, Spain, demonstrated robust efficacy and a good safety profile for the drug as a monotherapy and in co-administration with ramipril, an ACE inhibitor.
“This new data underlines the potential of SPP100 (Rasilez) in diabetic hypertensives, a segment of the hypertension population which is at a higher risk of having cardiovascular events than those hypertensive patients without diabetes,” commented Dr Jessica Mann, medical director for Speedel.
“SPP100 offers additional blood pressure control and is well tolerated when co-administered with ramipril – this is critical given that so many patients, especially those with hypertension and diabetes, are taking combination treatments in order to reach blood pressure targets,” Dr Mann continued.
Rasilez, a first-in-class once daily oral renin inhibitor, was developed through phase I and II clinical trials by Speedel before Novartis exercised its license-back option in 2002.
The FDA accepted for review in April 2006 Novartis’ new drug application for the drug as a treatment for hypertension both as monotherapy and in co-administration with other anti-hypertensives.